6609
Latest Information Update: 28 May 2020
At a glance
- Originator XuanZhu Pharma
- Class Anti-infectives
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infections
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Infections in China
- 11 Apr 2016 Preclinical trials in Infections in China (unspecified route) (XuanZhu Pharma pipeline, April 2016)